HCPCS Level II · Drugs administered other than oral method
J3320Injection, spectinomycin dihydrochloride, up to 2 gm
Terminated 12/31/2025
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J3320
J3320 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, spectinomycin dihydrochloride, up to 2 gm.
It was added to HCPCS effective 01/01/1982, and its current record took effect 01/01/2026.
It was terminated on 12/31/2025 and can't be billed for later dates of service.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Spectinomycn di-hcl inj
- Date added
- 01/01/1982
- Action effective
- 01/01/2026
- Termination date
- 12/31/2025
- BETOS
- O1E
Related J33xx codes
- J3300Injection, triamcinolone acetonide (triesence), preservative free, 1 mg
- J3301Injection, triamcinolone acetonide, not otherwise specified, 10 mg
- J3302Injection, triamcinolone diacetate, per 5 mg
- J3303Injection, triamcinolone hexacetonide, per 5 mg
- J3304Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
- J3315Injection, triptorelin pamoate, 3.75 mg
- J3316Injection, triptorelin, extended-release, 3.75 mg
- J3350Injection, urea, up to 40 gm
- J3357Ustekinumab, for subcutaneous injection, 1 mg
- J3358Ustekinumab, for intravenous injection, 1 mg
- J3360Injection, diazepam, up to 5 mg
- J3373Injection, vancomycin hydrochloride, 10 mg
Common questions about J3320
Is HCPCS J3320 still valid?
- No. J3320 was terminated on 12/31/2025.
Does Medicare cover J3320?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.